Upgrade to SI Premium - Free Trial

Kalaris Therapeutics (KLRS)

3.92 -0.15 (3.69%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/19/26)

Latest Headlines

Kalaris Therapeutics names Liisa Bayko as CFO July 20, 2026 8:00 AM - StreetInsider Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer July 20, 2026 8:00 AM - Globe NewsWire Kalaris reports positive TH103 Phase 1a data in neovascular AMD July 17, 2026 7:00 AM - StreetInsider Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts July 17, 2026 7:00 AM - Globe NewsWire Kalaris Therapeutics names Laurie Keating to its board July 6, 2026 4:05 PM - StreetInsider Kalaris Appoints Laurie Keating to Board of Directors July 6, 2026 4:05 PM - Globe NewsWire Kalaris to present TH103 Phase 1a data at retina specialists meeting June 23, 2026 8:00 AM - StreetInsider Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling June 23, 2026 8:00 AM - Globe NewsWire TD Cowen Starts Kalaris (KLRS) at Buy June 15, 2026 5:32 AM - StreetInsider Kalaris to Present at Clinical Trials at the Summit 2026 June 12, 2026 8:00 AM - Globe NewsWire Wedbush Starts Kalaris (KLRS) at Outperform May 14, 2026 6:53 AM - StreetInsider Kalaris (KLRS) PT Lowered to $25 at Citizens Ahead of Phase 1b/2 MAD data in 2027 May 13, 2026 5:08 AM - StreetInsider Kalaris Therapeutics (KLRS) Misses Q1 EPS by 46c May 12, 2026 4:26 PM - StreetInsider Raymond James on Kalaris (KLRS): 'We continue to expect Kalaris to resume dosing in 2Q26 ' May 12, 2026 12:21 PM - StreetInsider Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates May 12, 2026 8:00 AM - Globe NewsWire Full Article List